SMC accepts oral therapy for relapsing multiple sclerosis
Janssen’s Ponvory accepted for use within NHS Scotland for adults RRMS patients
Read More
Tag: Ponvory
MHRA nod for Janssen’s relapsing multiple sclerosis drug Ponvory
Phase III trial showed a reduction in annual relapse rate
Read More
EC approves Ponvory for relapsing MS
European approval follows the recent announcement of the FDA approval of Ponvory for RMS
Read More
Five new meds recommended in March CHMP decisions
The committee also recommended six extensions of current therapeutic indications
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
